SCHEMBL3191663

SCHEMBL3191663

O=C(NCc1ccccc1)c1cccc(O)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 4/20 0.71
HDAC2 Q92769 2/20 0.71
HDAC8 Q9BY41 2/20 0.71
ALDH1A1 P00352 3/20 0.62
GAA P10253 1/20 0.62
HSD17B10 Q99714 1/20 0.62
CFD P00746 1/20 0.62
HTT P42858 2/20 0.61
PPARG P37231 1/20 0.61
NR1H4 Q96RI1 2/20 0.60
EPHX2 P34913 1/20 0.60
EGFR P00533 1/20 0.60
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
MEN1 O00255 1/20 0.59
MAPT P10636 1/20 0.59
HPGD P15428 1/20 0.59
KMT2A Q03164 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9416647 0.92 ROCK2 (0.65) HDAC6HDAC2HDAC8ALDH1A1GAA
SCHEMBL5724150 0.90 ROCK2 (0.68) HDAC6HDAC2HDAC8ALDH1A1GAA
SCHEMBL9416590 0.90 ALDH1A1 (0.59) HDAC6HDAC2HDAC8ALDH1A1GAA
SCHEMBL11900328 0.90 HDAC6 (0.87) HDAC6HDAC2HDAC8ALDH1A1GAA
SCHEMBL22047184 0.86 PPARG (0.78) HDAC6HDAC2HDAC8ALDH1A1GAA
SCHEMBL6568470 0.86 EGFR (0.68) HDAC6HDAC2HDAC8ALDH1A1NR1H4
SCHEMBL3230417 0.86 RAB9A (0.62) HDAC6HDAC2HDAC8ALDH1A1HTT
SCHEMBL22972222 0.86 ROCK2 (0.67) HDAC6HDAC2HDAC8ALDH1A1GAA
SCHEMBL22972224 0.84 HPGD (0.57) HDAC6HDAC2HDAC8ALDH1A1GAA
SCHEMBL457082 0.84 HDAC6 (0.79) HDAC6HDAC2HDAC8ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220388979-A1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2022-12-08 US disclosed
WO-2021023888-A1 ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2021-02-11 WO disclosed
CN-105916506-B Quinazoline derivatives as inhibitors of TAM family kinases 圣诺康生命科学公司 2020-01-07 CN disclosed
EP-3071204-B1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORP (CA) 2019-02-20 EP disclosed
EP-3071204-B1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORP (CA) 2019-02-20 EP disclosed
US-9771333-B2 Quinazoline derivatives as TAM family kinase inhibitors SIGNALCHEM LIFESCIENCES CORP. (CA) 2017-09-26 US disclosed
US-9771333-B2 Quinazoline derivatives as TAM family kinase inhibitors SIGNALCHEM LIFESCIENCES CORP. (CA) 2017-09-26 US disclosed
US-9771333-B2 Quinazoline derivatives as TAM family kinase inhibitors SIGNALCHEM LIFESCIENCES CORP. (CA) 2017-09-26 US disclosed
US-20160297775-A1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORP (CA) 2016-10-13 US disclosed
US-20160297775-A1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORP (CA) 2016-10-13 US disclosed
US-20160297775-A1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORP (CA) 2016-10-13 US disclosed
CN-105916506-A Quinazoline derivatives as inhibitors of TAM family kinases 圣诺康生命科学公司 2016-08-31 CN disclosed
WO-2015077375-A1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS SIGNALCHEM LIFESCIENCES CORP. (CA) 2015-05-28 WO disclosed
US-20100016379-A1 Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors IRM LLC (BM) 2010-01-21 US disclosed
US-20100016379-A1 Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors IRM LLC (BM) 2010-01-21 US disclosed
US-20100016379-A1 Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors IRM LLC (BM) 2010-01-21 US disclosed
EP-2018166-A2 TEREPHTHALAMATE COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS HIV INTEGRASE INHIBITORS IRM LLC (BM) 2009-01-28 EP disclosed
WO-2008073138-A2 TEREPHTHALAMATE COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS HIV INTEGRASE INHIBITORS IRM LLC (BM) 2008-06-19 WO disclosed
WO-2008073138-A2 TEREPHTHALAMATE COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS HIV INTEGRASE INHIBITORS IRM LLC (BM) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220388979-A1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABL1, PHKB, EEF2K HDAC6 797/4885HDAC2 1446/4885HDAC8 1337/4885
US-20100016379-A1 Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors TYMP, TYMS, IMPDH1 HDAC6 1326/4885HDAC2 937/4885HDAC8 388/4885
US-20160297775-A1 QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS MAP3K5, MAP3K1, MAP3K2 HDAC6 1451/4885HDAC2 1173/4885HDAC8 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.